TuHURA Biosciences’ (HURA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of TuHURA Biosciences (NASDAQ:HURA – Free Report) in a report published on Tuesday morning,Benzinga reports. HC Wainwright also issued estimates for TuHURA Biosciences’ Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.46) EPS, Q1 2027 earnings at ($0.09) EPS, Q2 2027 earnings at ($0.10) EPS, Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.10) EPS and FY2027 earnings at ($0.39) EPS.

HURA has been the subject of several other reports. Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Thursday, October 15th. Citizens Jmp reaffirmed a “market outperform” rating and issued a $9.00 price target on shares of TuHURA Biosciences in a report on Tuesday, August 18th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $9.50.

Get Our Latest Stock Report on HURA

TuHURA Biosciences Stock Down 0.7%

TuHURA Biosciences stock opened at $1.36 on Tuesday. TuHURA Biosciences has a 1-year low of $0.41 and a 1-year high of $3.43. The firm has a market capitalization of $89.43 million, a price-to-earnings ratio of -2.72 and a beta of -0.23. The company has a current ratio of 0.47, a quick ratio of 0.18 and a debt-to-equity ratio of 0.49. The firm has a 50 day simple moving average of $1.86 and a 200 day simple moving average of $2.02.

TuHURA Biosciences (NASDAQ:HURA – Get Free Report) last posted its quarterly earnings results on Friday, November 13th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.04. On average, analysts predict that TuHURA Biosciences will post -0.50 earnings per share for the current year.

Institutional Investors Weigh In On TuHURA Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of HURA. BlackRock Inc. bought a new position in shares of TuHURA Biosciences in the 2nd quarter worth $1,615,000. Jefferies Financial Group Inc. purchased a new stake in shares of TuHURA Biosciences during the 2nd quarter valued at $98,000. Invst LLC purchased a new stake in shares of TuHURA Biosciences during the 2nd quarter valued at $99,000. Hsbc Holdings PLC bought a new stake in shares of TuHURA Biosciences during the 2nd quarter worth $69,000. Finally, Sanctuary Advisors LLC bought a new stake in shares of TuHURA Biosciences during the 2nd quarter worth $49,000. 0.62% of the stock is owned by hedge funds and other institutional investors.

Top TuHURA Biosciences Stories

These are some of the HURA stories that stood out recently:

  • Positive Sentiment: HC Wainwright raised its 2026 and 2027 earnings-per-share forecasts, including improving its FY2027 estimate from a loss of $0.61 to a loss of $0.39 per share. It also lifted estimates for each quarter from Q4 2026 through Q4 2027 and maintained its “Buy” rating. TuHURA analyst estimates
  • Positive Sentiment: Brookline Capital Markets also improved its forecasts: its FY2026 and FY2027 loss estimates narrowed, and it now projects a return to positive EPS in FY2029 and higher earnings in FY2030. These longer-term projections may bolster optimism but depend on future execution. TuHURA analyst estimates
  • Neutral Sentiment: Overall, the revisions suggest analysts expect smaller losses, but TuHURA is still forecast to report losses in the near term. The news contains no new operating or clinical update. HC Wainwright’s “Buy” rating was also reported separately. TuHURA earns Buy rating from HC Wainwright

TuHURA Biosciences Company Profile

(Get Free Report)

TuHURA Biosciences is a clinical-stage biotechnology company developing immunotherapies for cancer. Its research focuses on treatments intended to stimulate the immune system and address mechanisms that allow tumors to evade immune attack. The company’s pipeline includes IFx-2.0, an investigational intratumoral immunotherapy being studied for use with checkpoint inhibitors, as well as antibody programs targeting immune-regulating pathways. TuHURA has no marketed products, and its candidates remain in development.

Further Reading

Analyst Recommendations for TuHURA Biosciences (NASDAQ:HURA)

Receive News & Ratings for TuHURA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TuHURA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.